Patents by Inventor Craig C. Mello
Craig C. Mello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10731155Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: November 15, 2017Date of Patent: August 4, 2020Assignee: UNIVERSITY OF MASSACHUSETTSInventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Patent number: 10358653Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: January 22, 2016Date of Patent: July 23, 2019Assignees: The Carnegie Institution of Washington, The University of MassachusettsInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20180163206Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: November 15, 2017Publication date: June 14, 2018Inventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Patent number: 9850487Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: September 15, 2015Date of Patent: December 26, 2017Assignee: UNIVERSITY OF MASSACHUSETTSInventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Publication number: 20160362685Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: September 15, 2015Publication date: December 15, 2016Inventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Publication number: 20160208280Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: January 22, 2016Publication date: July 21, 2016Inventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig c. Mello
-
Publication number: 20160102309Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: September 15, 2015Publication date: April 14, 2016Inventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Patent number: 9175287Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: September 9, 2013Date of Patent: November 3, 2015Assignee: University of MassachusettsInventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Patent number: 9102939Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: October 8, 2012Date of Patent: August 11, 2015Assignees: The Carnegie Institution of Washington, The University of MassachusettsInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20150133318Abstract: The instant invention is based, at least in part, on the identification of novel methods for the enzymatic enrichment of capped RNAs. The invention provides, e.g., methods for enrichment of capped RNAs, kits for making such capped RNAs, and compositions of enriched RNAs or cDNA libraries derived therefrom.Type: ApplicationFiled: April 24, 2014Publication date: May 14, 2015Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Craig C. MELLO, Weifeng GU
-
Publication number: 20140350083Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20140179760Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: September 9, 2013Publication date: June 26, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Phillip D. ZAMORE, Juanita MCLACHLAN, Gyorgy HUTVAGNER, Alla GRISHOK, Craig C. MELLO
-
Patent number: 8580754Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: October 1, 2007Date of Patent: November 12, 2013Assignees: Carnegie Institution of Washington, The University of MassachusettsInventors: Andrew Z. Fire, Stephen A. Kostas, Mary K. Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Patent number: 8557785Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: March 23, 2010Date of Patent: October 15, 2013Assignee: University of MassachusettsInventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Patent number: 8530438Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: March 19, 2010Date of Patent: September 10, 2013Assignee: University of MassachusettsInventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Publication number: 20130230492Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: October 8, 2012Publication date: September 5, 2013Applicants: THE UNIVERSITY OF MASSACHUSETTS, CARNEGIE INSTITUTION OF WASHINGTONInventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Publication number: 20130029425Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: ApplicationFiled: July 25, 2012Publication date: January 31, 2013Inventors: Andrew Fire, Stephen Kostas, Mary Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Patent number: 8283329Abstract: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.Type: GrantFiled: September 28, 2007Date of Patent: October 9, 2012Assignees: The Carnegie Institution of Washington, The University of MassachusettsInventors: Andrew Z. Fire, Stephen A. Kostas, Mary K. Montgomery, Lisa Timmons, SiQun Xu, Hiroaki Tabara, Samuel E. Driver, Craig C. Mello
-
Patent number: 8232260Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vitro with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: GrantFiled: February 21, 2011Date of Patent: July 31, 2012Assignee: University of MassachusettsInventors: Phillip D. Zamore, Juanita McLachlan, Gyorgy Hutvagner, Alla Grishok, Craig C. Mello
-
Publication number: 20110207224Abstract: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vitro with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.Type: ApplicationFiled: February 21, 2011Publication date: August 25, 2011Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Phillip D. ZAMORE, Juanita MCLACHLAN, Gyorgy HUTVAGNER, Alla GRISHOK, Craig C. MELLO